Sirion advances two products into Phase III

Article

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The programmes will evaluate ST-601 as a therapy for the treatment of anterior uveitis and ST-603 as a potential therapy for dry eye syndrome.

The addition of these two Phase III studies brings the number of Sirion's active clinical programmes to five.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.